P20
Neo-adjuvant Pembrolizumab in Primary Stage IV Ovarian CancerNivolumab, Ipilimumab and COX2-inhibition in Early Stage Colon Cancer: an Unbiased Approach for Signals of SensitivityStudy Evaluating the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD), and Therapeutic Activity of Selicrelumab (RO7009789) With Vanucizumab or Bevacizumab in Participants With Metastatic Solid TumorsCatheter Ablation vs. Standard Conventional Treatment in Patients With LV Dysfunction and AFStudy to Assess the Non-inferiority of Pamorelin® 11,25mg SC Injected Versus Pamorelin® 11,25mg IM Injected in Patients Suffering From Advanced Prostate Cancer (PAMOJECT)Neoadjuvant Chemotherapy in HER2 Positive Breast Cancer, TRAIN-2An Investigational Immuno-therapy Study to Assess the Safety, Tolerability and Effectiveness of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid TumorsDose Individualization of Pemetrexed - IMPROVE-IDose Individualization of Pemetrexed - IMPROVE-IIIDose Individualization of Pemetrexed - IMPROVE-IIVinorelbine in Advanced BRAF-like Colon CancerBlinatumomab Added to Prephase and Consolidation Therapy in Precursor B-acute Lymphoblastic Leukemia in Adults.ctDNA as a Biomarker for Treatment Response in HNSCCCAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 DiabetesM7824 Versus Pembrolizumab as a First-line (1L) Treatment in Participants With Programmed Death-ligand 1 (PD-L1) Expressing Advanced Non-small Cell Lung Cancer (NSCLC)18F-PD-L1 PET/CT in Nivolumab Treated Patients With NSCLCNeoadjuvant Capecitabine, Oxaliplatin, Docetaxel and Atezolizumab in Resectable Gastric and GE-junction Cancer (PANDA)"Wait-and-see" Policy for Complete Responders After Chemoradiotherapy for Rectal CancerEndocrine Therapy Plus CDK4/6 in First or Second Line for Hormone (SONIA) Receptor Positive Advanced Breast CancerSecond and Third Look Laparoscopy in pT4 Colon Cancer Patients for Early Detection of Peritoneal MetastasesMonitoring MRI Changes Before and During Radiotherapy Treatment of Brain TumorsNeo-Adjuvant Bladder Urothelial Carcinoma COmbination-immunotherapyA Study of RO6958688 in Participants With Locally Advanced and/or Metastatic Carcinoembryonic Antigen Positive Solid TumorsGLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)
P6153
Q58407764-3D33646E-3A2C-41DB-B21F-011D57C31128Q58846075-85DD686B-A8AF-4245-805C-E3780FDCA2BFQ61070971-C7C1B876-DD5E-445B-8E57-CB7EB7BECBA2Q61914651-4C90B05B-85A0-4D42-80F3-2FCB6C1F3E47Q61924707-65EBBEE9-F226-42CF-B338-F0056DFB4BFCQ61969619-AD59CA3A-929A-4D06-B2F9-C617B48E0B08Q61975539-ACD8BF41-EC4A-4885-BF94-C789758FC9F0Q62024885-8DE96951-EAE0-4E40-B103-42E7EE2C1520Q62024942-961229CC-1714-4289-9639-AE336B2B464BQ62024944-7DA644F3-1DF4-456C-B905-8EAD179D1B56Q62810829-CEFC1E85-1FE5-4AA5-AF59-92E538CF6F61Q62811927-812DE264-9E09-43F5-91C1-EFA0A2002255Q62812134-0332DD1F-012E-4DA0-9D4F-15637194FACFQ63340041-5CDC4BD9-24BD-43D2-95B4-99CEAD838C78Q63394793-29DD2031-A0BB-4825-8B76-F3987AC90C17Q63398934-000B9069-6A78-4BD6-AB69-6D895EA50622Q63398934-06D401D1-CD30-4B25-906A-A077E3767275Q63401172-97E94496-BBB6-4EE2-9AA5-A7EECD7C0C52Q63401498-FC0338CA-673A-4233-A09B-334CD4E25E90Q63401675-B434267D-ED90-415F-9304-5E961B5EC3AEQ63401853-71932593-77B7-4701-80EA-7AB452C4A843Q63404113-531515E6-F319-4FE0-BF9B-4288B9924A1DQ63405668-6FF723B9-74D9-4DBB-831C-168F583DF3ACQ63571407-66D5E54C-9E0D-46FF-8C31-A68A136516CCQ64123586-25D60647-98F3-42D5-9182-D46EE7B381C7
P6153
description
Krankenhaus in Amsterdam
@de
Krankenhaus in Amsterdam
@de-at
Krankenhaus in Amsterdam
@de-ch
cancersjukhus i Amsterdam, Nederländerna
@sv
clínica oncológica de Ámsterdam
@es
griya sakit
@jv
hospital de Países Baxos
@ast
hôpital
@fr
kliniek voor behandeling van kanker
@nl
oncology clinic in Amsterdam
@en
name
Antoni van Leeuwenhoekziekenhuis
@da
Antoni van Leeuwenhoekziekenhuis
@de
Antoni van Leeuwenhoekziekenhuis
@de-at
Antoni van Leeuwenhoekziekenhuis
@de-ch
Antoni van Leeuwenhoekziekenhuis
@en
Antoni van Leeuwenhoekziekenhuis
@es
Antoni van Leeuwenhoekziekenhuis
@nl
Antoni van Leeuwenhoekziekenhuis
@sv
type
label
Antoni van Leeuwenhoekziekenhuis
@da
Antoni van Leeuwenhoekziekenhuis
@de
Antoni van Leeuwenhoekziekenhuis
@de-at
Antoni van Leeuwenhoekziekenhuis
@de-ch
Antoni van Leeuwenhoekziekenhuis
@en
Antoni van Leeuwenhoekziekenhuis
@es
Antoni van Leeuwenhoekziekenhuis
@nl
Antoni van Leeuwenhoekziekenhuis
@sv
altLabel
AVL
@de
AVL
@nl
Antoni van Leeuwenhoek Hospital
@de
Antoni van Leeuwenhoek Ziekenhuis
@de
Antoni van Leeuwenhoek Ziekenhuis
@en
Antoni van Leeuwenhoek Ziekenhuis
@es
Antoni van Leeuwenhoek Ziekenhuis
@nl
NCI
@de
Neterlands Cancer Institute
@en
Neterlands Cancer Institute
@es
prefLabel
Antoni van Leeuwenhoekziekenhuis
@da
Antoni van Leeuwenhoekziekenhuis
@de
Antoni van Leeuwenhoekziekenhuis
@de-at
Antoni van Leeuwenhoekziekenhuis
@de-ch
Antoni van Leeuwenhoekziekenhuis
@en
Antoni van Leeuwenhoekziekenhuis
@es
Antoni van Leeuwenhoekziekenhuis
@nl
Antoni van Leeuwenhoekziekenhuis
@sv
P214
P244
P131
P17
P214
P2427
grid.430814.a
P244
P276
P373
Antoni van Leeuwenhoekziekenhuis
P625
Point (4.8257222222222 52.350027777778)
P6375
Plesmanlaan 121, 1066 CX Amsterdam
@nl
P669
P6773
P6782
P691
nlk20030137576
P7859
lccn-n83829224